Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 7/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20691302 | 0.93 | SLC29A1 (0.64) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL31160245 | 0.93 | SLC29A1 (0.64) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL30614562 | 0.88 | SLC29A1 (0.71) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL34996 | 0.86 | SLC29A1 (0.73) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL8595980 | 0.85 | SLC29A1 (0.59) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL28418625 | 0.84 | SLC29A1 (0.64) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL7254473 | 0.83 | HSD17B10 (0.53) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL7254474 | 0.83 | HSD17B10 (0.53) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL20579724 | 0.83 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL1322160 | 0.83 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694867-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3676279-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10953032-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3694867-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200253997-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3676279-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-111344297-A | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-111051328-A | Cyclic dinucleotides as anticancer agents | 百时美施贵宝公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019074887-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019046500-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253997-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | SLC29A1 358/4885CYP3A4 3005/4885LMNA 1999/4885 |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | SLC29A1 537/4885CYP3A4 3633/4885LMNA 1855/4885 |
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | SLC29A1 367/4885CYP3A4 3042/4885LMNA 2058/4885 |
| US-10953032-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | SLC29A1 358/4885CYP3A4 3005/4885LMNA 1999/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | SLC29A1 367/4885CYP3A4 3042/4885LMNA 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.